Myostatin and Duchenne Muscular Dystrophy: What the Trials Showed

The disease that was supposed to prove the field. Duchenne muscular dystrophy was the obvious first indication for myostatin inhibitors: a fatal childhood muscle-wasting disease with no real treatment, a clean biological rationale, and a community desperate for anything.

Twenty years later, the scoreboard is brutal. Eight major programs, three sponsors that walked away, and a single uncomfortable pattern: myostatin inhibitors keep showing biological signals in DMD without changing how boys walk, climb, or stand.

Why DMD looked like the perfect first indication

The biology made the bet obvious. DMD is caused by mutations in the dystrophin gene that destroy the protein anchoring muscle fibers to the membrane during contraction. Without dystrophin, muscle fibers tear, die, and are replaced by fat and scar tissue.

The replacement is the killer. Boys with Duchenne typically lose the ability to walk between ages 8 and 14, lose upper body function in their teens, and die from respiratory or cardiac failure in their 20s or 30s.

Myostatin inhibition was supposed to slow that timeline. If you could keep the remaining functional muscle bigger and stronger, the thinking went, you could buy years of ambulation and function before the disease overwhelmed it.

The animal data was striking. Mdx mice (the genetic mouse model of DMD) treated with anti-myostatin antibodies showed 20-30% increases in muscle mass, improved force generation, and less fibrosis at autopsy. Crossing mdx mice with myostatin knockouts produced even larger improvements.

The leap from mouse to boy never quite worked.

The first wave: MYO-029 and Wyeth

The first human trial set the pattern. MYO-029 (stamulumab) was a humanized monoclonal antibody developed by Wyeth that bound and neutralized circulating myostatin. The Phase 1/2 trial enrolled 116 adult patients with various muscular dystrophies (including BMD and FSHD) at three escalating doses.

The 2008 readout disappointed. MYO-029 was safe and tolerable, but the trial did not show improvements in muscle strength or function across the dystrophy populations studied. The signal in DMD specifically was modest at best.

Wyeth ended the DMD development in 2008. The drug remains relevant because it proved the safety of myostatin neutralization in humans, which opened the door for everything that came after.

The mechanism, biology, and full clinical record of MYO-029 are covered in our anti-myostatin antibody article.

ACE-031 and the bleeding problem

The second wave failed harder. ACE-031 (ramatercept) was a soluble ActRIIB-Fc fusion protein from Acceleron that trapped activin, myostatin, and GDF-11 simultaneously.

The Phase 2 trial in ambulatory DMD boys started in 2010 with biological promise. Lean mass increased visibly. Boys were physically bigger after treatment.

The safety signal stopped the trial. Multiple participants developed epistaxis (nosebleeds) and telangiectasia (small visible blood vessels on the skin), reflecting the fact that ActRIIB-Fc traps more than just myostatin. It also blocks BMP9 and BMP10, two ligands critical for vascular endothelial health.

Acceleron paused the trial in 2011, formally discontinued ACE-031 for DMD in 2013, and pivoted the ActRIIB-Fc platform toward red blood cell disorders (where it became luspatercept). The full story is in our ACE-031 coverage.

Domagrozumab (Pfizer, BMS-986089) and the futility readout

The third wave was supposed to be cleaner. Domagrozumab (PF-06252616, originally BMS-986089) was a humanized monoclonal antibody from Pfizer that targeted free, mature myostatin without touching activin A or BMPs. The selectivity was the pitch: get the muscle effect without the bleeding signal.

The Phase 2 trial enrolled 121 ambulatory boys with DMD aged 6-16 across multiple centers. The primary endpoint was change in 4-stair climb time after 48 weeks of dosing.

The 2018 readout failed. Domagrozumab did not produce a statistically significant improvement in 4-stair climb time, and Pfizer ended the program for DMD shortly after. Lean mass increased, but function did not follow.

The selectivity strategy did not rescue the underlying problem.

RG6206 / taldefgrobep alfa and the SPITFIRE trial

Roche took the most expensive swing. RG6206 (also called RO7239361) was an anti-myostatin adnectin protein developed by Bristol-Myers Squibb and licensed to Roche/Genentech in 2017. Unlike an antibody, it used a small protein scaffold to bind myostatin with high affinity and a different pharmacokinetic profile.

The SPITFIRE trial (WN40227) was a Phase IIb/III study enrolling roughly 250 ambulatory DMD boys. The primary endpoint was change from baseline in the North Star Ambulatory Assessment (NSAA) total score after 48 weeks.

Roche announced the discontinuation on November 6, 2019. A pre-planned futility analysis concluded that RG6206 "was highly unlikely to demonstrate clinical benefit as defined by meeting the primary endpoint." Safety was not the issue; the drug simply did not move the function score.

Roche held community webinars two days later and committed to sharing the trial data through the Trajectory Analysis Project (cTAP) consortium. The drug was eventually picked up by Biohaven and rebranded as taldefgrobep alfa for muscle-preserving weight loss, where it now lives instead.

Landogrozumab (Eli Lilly, LY2495655)

The Lilly program ended quietly. LY2495655 was a humanized monoclonal anti-myostatin antibody that Eli Lilly developed primarily for sarcopenia and cancer-related weakness, with parallel exploration in DMD.

Lilly discontinued LY2495655 in 2015 after disappointing functional data in the older-adult populations it tested. The DMD program never reached a definitive late-stage readout.

Apitegromab and the SMA hand-off

The one program that worked changed lanes. Apitegromab (SRK-015) from Scholar Rock is a monoclonal antibody that selectively binds latent (pro-) myostatin and blocks its activation, leaving mature myostatin alone.

That selectivity made it different. Scholar Rock pursued spinal muscular atrophy (SMA) instead of Duchenne. SMA muscle is wasting from motor-neuron loss rather than membrane fragility, which means the muscle structure is more intact and more responsive to mass-preservation strategies.

The TOPAZ Phase 2 and SAPPHIRE Phase 3 trials in SMA showed meaningful motor function improvements on top of background SMA therapy. The FDA approval for SMA arrived in 2024. The DMD development path was not pursued.

The apitegromab story is covered in detail in our dedicated apitegromab article.

What every DMD myostatin trial showed in one table

Why myostatin inhibitors keep losing in DMD

Five reasons, layered. None of them is unique to one drug.

First, dystrophic muscle is structurally fragile. Adding mass to a fiber that lacks dystrophin does not make the membrane stronger. It can make the tearing worse under contraction load, because a bigger fiber generating more force still has nothing anchoring it to the membrane.

Second, the timing window is narrow. By the time a boy is enrolled in a trial (typically age 4-12), significant muscle has already been replaced with fat and fibrosis. Myostatin inhibition cannot regenerate that tissue; it can only act on the fibers that remain. The remaining pool keeps shrinking as the disease progresses.

Third, the functional endpoints are noisy. The 4-stair climb, 6-minute walk test, and North Star Ambulatory Assessment all have meaningful trial-to-trial variability in DMD patients on background steroids. A small biological effect can be statistically washed out.

Fourth, steroids change the playing field. Standard-of-care corticosteroids (deflazacort, prednisone) already act on some of the same atrophic pathways myostatin inhibitors would target. The room for an additional pure mass effect is smaller than it looks on paper.

Fifth, dystrophin matters more than mass. Programs that target dystrophin directly (exon skipping for specific mutations, gene therapy with mini-dystrophin) have shown clearer dystrophin restoration on muscle biopsy and have produced FDA approvals. They are doing what myostatin inhibition cannot: addressing the root cause.

A 2020 Cells review (Domingues-Faria and colleagues) summarized the field as "the failed clinical story" — not because the mechanism was wrong, but because mechanism alone was never going to be enough.

What is still in play for DMD

The combination story is the live thesis. If gene therapy or exon skipping can put dystrophin back into a meaningful fraction of fibers, myostatin inhibition could in theory amplify the gain by enlarging those restored fibers.

Several lines of research are testing this:

• Combining anti-myostatin antibodies with exon-skipping antisense oligonucleotides in mdx mouse models
• Pairing AAV-microdystrophin gene therapy with follistatin overexpression
• Exploring oral myostatin inhibitors or muscle-targeted gene editing approaches as adjuncts rather than standalone therapy

Whether any of this reaches a Phase 3 DMD trial in the next five years is unclear. The early reception from boys' families and from the DMD foundations has been cautious after a decade of disappointing readouts.

Trichostatin A, a histone deacetylase inhibitor, has shown utrophin-upregulating effects that partially compensate for dystrophin loss in mdx mice — a different angle that does not rely on myostatin at all. The counter-intuitive myostatin biology of trichostatin is covered in our trichostatin A and myostatin article.

What this means for boys and families today

The honest framing. No myostatin inhibitor is currently approved for Duchenne muscular dystrophy. None has shown a benefit large enough to register on standard ambulation endpoints.

This matters because online discussions sometimes still describe myostatin inhibitors as a "near-term" DMD treatment. They are not. The drugs that families should ask their neurologists about today are corticosteroids, exon-skipping drugs (for amenable mutations), Elevidys (delandistrogene moxeparvovec gene therapy, for boys 4 and older with confirmed DMD mutation), and supportive care.

Myostatin inhibition may yet become part of the DMD picture in combination with dystrophin-restoring approaches. But it is not a current option, and any clinic or peptide vendor selling something for DMD muscle preservation is not operating in the evidence base.

For broader context on the myostatin inhibitor pipeline, see our best myostatin inhibitor overview and myostatin inhibitor drug review. For the genetic backdrop on what happens when myostatin is absent in humans, see myostatin deficiency in humans and low myostatin.

Sources

• Roche/Genentech announcement of RG6206 discontinuation, November 2019
• Pharmaphorum coverage of Roche dropping the myostatin inhibitor for DMD
• Domingues-Faria et al, "The Failed Clinical Story of Myostatin Inhibitors against Duchenne Muscular Dystrophy", Cells 2020, 9(12):2657
• Current Opinion in Neurology, "The elusive promise of myostatin inhibition for muscular dystrophy"
• Rare Disease Advisor, novel myostatin inhibitor coverage
• Scholar Rock apitegromab program updates
• Parent Project MD position statement on myostatin inhibition

Frequently Asked Questions